Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion.

Tumor vasculature is a promising therapeutic target in glioblastoma. Imaging tumor blood flow may help assess the efficacy of anti-angiogenic treatments. We determined the clinical usefulness of stable xenon CT performed preoperatively in patients with glioblastoma. This is a prospective cohort study. We determined absolute tumor blood flow before surgery in 38 patients with glioblastoma using stable xenon CT. We also histologically examined tumor specimens obtained from surgery and quantified their vascularity (by CD31 and CD105 immunostain), necrosis (by hematoxylin and eosin stain), and the presence of neuronal processes (by neurofilament immunostain). According to the xenon CT blood flow map, there are 3 types of glioblastoma. Type I glioblastomas have unimodal high blood flow histograms; histologically there is little necrosis and vascular proliferation. Type II glioblastomas have unimodal low blood flow histograms; histologically there is prominent necrosis and vascular proliferation. We propose that in type II glioblastoma, the abnormal vessels induced by hypoxia are inefficient at promoting blood flow. Type III glioblastomas have multimodal blood flow histograms. Histologically there is significant neuronal tissue within the tumor. Patients with type III glioblastomas were more likely to develop a post-surgical deficit, consistent with the inclusion of normal tissue within the tumor. Preoperative measurement of absolute blood flow with stable xenon CT in patients with glioblastoma predicts key biological features of the tumor and may aid surgical planning.

[1]  P. Black,et al.  Angiogenesis in Brain Tumors , 2013, Cancer Treatment and Research.

[2]  Kim Mouridsen,et al.  T1- and T*2-Dominant Extravasation Correction in DSC-MRI: Part I—Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  N. Brünner,et al.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids , 2011, Journal of Neuro-Oncology.

[4]  M. Papadopoulos,et al.  Serum Angiogenic Profile of Patients with Glioblastoma Identifies Distinct Tumor Subtypes and Shows That TIMP-1 Is a Prognostic Factor , 2010 .

[5]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[6]  A. Alavi,et al.  Molecular imaging (PET) of brain tumors. , 2009, Neuroimaging clinics of North America.

[7]  M. Law,et al.  Magnetic resonance perfusion and permeability imaging in brain tumors. , 2009, Neuroimaging clinics of North America.

[8]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[9]  T E Yankeelov,et al.  A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation , 2009, Physics in medicine and biology.

[10]  K. Khalili,et al.  Molecular mechanisms of necrosis in glioblastoma: The role of glutamate excitotoxicity , 2009, Cancer biology & therapy.

[11]  Dorothee P. Auer,et al.  Quantitative imaging biomarkers in neuro-oncology , 2009, Nature Reviews Clinical Oncology.

[12]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[13]  A. Unterberg,et al.  The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. , 2009, Anti-cancer agents in medicinal chemistry.

[14]  Tracy T Batchelor,et al.  Angiogenesis as a therapeutic target in malignant gliomas. , 2009, The oncologist.

[15]  V. Amberger-Murphy Hypoxia helps glioma to fight therapy. , 2009, Current cancer drug targets.

[16]  R. Jensen,et al.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target , 2009, Journal of Neuro-Oncology.

[17]  Tracy T Batchelor,et al.  Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas , 2008, Current opinion in neurology.

[18]  C. Gladson,et al.  New molecular targets in angiogenic vessels of glioblastoma tumours , 2008, Expert Reviews in Molecular Medicine.

[19]  M. J. van den Bent,et al.  Molecular targeted therapies and chemotherapy in malignant gliomas , 2007, Current opinion in oncology.

[20]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[21]  Alan Koretsky,et al.  Technological advances in MRI measurement of brain perfusion , 2005, Journal of magnetic resonance imaging : JMRI.

[22]  M. Matsuda,et al.  Threshold of regional cerebral blood flow for infarction in patients with acute cerebral ischemia. , 2005, Journal of neuroradiology. Journal de neuroradiologie.

[23]  Daniel J Brat,et al.  Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.

[24]  R. Selway,et al.  Posterior lumbar interbody fusion for revision disc surgery: review of 50 cases in which carbon fiber cages were implanted. , 2001, Journal of neurosurgery.

[25]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[26]  A. Ruifrok,et al.  Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.

[27]  P. Black,et al.  Anti-angiogenic Treatment Strategies for Malignant Brain Tumors , 2000, Journal of Neuro-Oncology.

[28]  R. Roemer,et al.  Cerebral bloodflow in and around spontaneous malignant gliomas. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[29]  S. Kety,et al.  THE NITROUS OXIDE METHOD FOR THE QUANTITATIVE DETERMINATION OF CEREBRAL BLOOD FLOW IN MAN: THEORY, PROCEDURE AND NORMAL VALUES. , 1948, The Journal of clinical investigation.

[30]  A. Chakravarti,et al.  Molecular profiling in glioblastoma: Prelude to personalized treatment , 2009, Current oncology reports.

[31]  S. Niclou,et al.  Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. , 2009, Expert opinion on therapeutic targets.

[32]  E. Fainardi,et al.  Cerebral blood flow thresholds predicting new hypoattenuation areas due to macrovascular ischemia during the acute phase of severe and complicated aneurysmal subarachnoid hemorrhage. A preliminary study. , 2008, Acta neurochirurgica. Supplement.

[33]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[34]  M. Westphal,et al.  Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.

[35]  D. Van Roost,et al.  Changes of Cerebral Blood Flow Following Dexamethasone Treatment in Brain Tumour Patients. A Xe/CT Study , 2001, Acta Neurochirurgica.

[36]  S. Takeuchi,et al.  Haemodynamic Evaluation of Cerebral Gliomas Using XeCT , 1998, Acta Neurochirurgica.

[37]  J. Palmer,et al.  Statistical modelling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. , 1991, British journal of neurosurgery.

[38]  D. Gur,et al.  Stable xenon CT/CBF imaging: laboratory and clinical experience. , 1987, Advances and technical standards in neurosurgery.